お知らせ • Oct 19
PLx Pharma Winddown Corp. Files Form 15 PLx Pharma Winddown Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share. お知らせ • Jul 10
Plx Pharma Winddown Corp. Announces Executive Changes PLx Pharma Winddown Corp. on June 30, 2023, the Company terminated the employment of Natasha Giordano, President, and of Rita O’Connor, Head of Manufacturing and Supply Chain. Effective as of July 1, 2023, Ms. O’Connor entered into a consulting arrangement with the Company. お知らせ • Feb 14
PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC On February 7, 2023, PLx Pharma Inc. received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the Audit Committee") of the Board of Directors of the Company (the Board") be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company's Audit Committee is currently comprised of only two independent directors resulting in the noncompliance. In accordance with Nasdaq Listing Rule 5605(c)(4), the Company is granted a cure period in order to regain compliance with Nasdaq Listing Rule 5605 lasting until the earlier of the Company's next annual stockholders' meeting or January 19, 2024 or, if the next annual stockholders' meeting is held before July 18, 2023, then no later than July 18, 2023. The Company's common stock will continue to be listed and traded on the Nasdaq Capital Market during the compliance period, subject to the Company's compliance with the other continued listing requirements of the Nasdaq Capital Market. お知らせ • Jan 22
PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board On January 19, 2023, John W. Hadden II, a member of the Board of Directors of PLx Pharma Inc., resigned from the Board effective immediately. Mr. Hadden's resignation is not the result of any disagreement with the Company. Major Estimate Revision • May 20
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$27.4m to US$19.0m. EPS estimate increased from -US$2.32 to -US$1.77 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$16.33 to US$14.00. Share price rose 11% to US$2.87 over the past week. Price Target Changed • Apr 27
Price target decreased to US$16.33 Down from US$21.50, the current price target is an average from 4 analysts. New target price is 406% above last closing price of US$3.23. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$2.29 next year compared to a net loss per share of US$2.06 last year. Recent Insider Transactions • Mar 24
Key Executive recently bought US$50k worth of stock On the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months. Recent Insider Transactions • Mar 21
Key Executive recently bought US$50k worth of stock On the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months. Recent Insider Transactions • Mar 18
Key Executive recently bought US$50k worth of stock On the 15th of March, Rita O'Connor bought around 14k shares on-market at roughly US$3.66 per share. This was the largest purchase by an insider in the last 3 months. This was Rita's only on-market trade for the last 12 months. Breakeven Date Change • Mar 13
No longer forecast to breakeven The 3 analysts covering PLx Pharma no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$6.50m in 2024. New consensus forecast suggests the company will make a loss of US$21.4m in 2024. Major Estimate Revision • Aug 13
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$5.73m to US$9.97m. EPS estimate fell from -US$1.32 to -US$2.07 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$21.50 unchanged from last update. Share price fell 8.0% to US$16.97 over the past week. Major Estimate Revision • Jul 21
Consensus revenue estimates fall to US$5.73m The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from US$7.27m to US$5.73m. Forecast losses increased from -US$1.29 to -US$1.32 per share. Pharmaceuticals industry in the US expected to see average net income growth of 11% next year. Consensus price target up from US$16.00 to US$21.50. Share price rose 15% to US$19.63 over the past week. Price Target Changed • Jul 21
Price target increased to US$21.50 Up from US$16.00, the current price target is an average from 3 analysts. New target price is 7.0% above last closing price of US$20.10. Stock is up 584% over the past year. Recent Insider Transactions • Jun 16
Executive Chairman recently bought US$100k worth of stock On the 14th of June, Michael Valentino bought around 8k shares on-market at roughly US$12.48 per share. This was the largest purchase by an insider in the last 3 months. Michael has been a buyer over the last 12 months, purchasing a net total of US$300k worth in shares. Major Estimate Revision • May 21
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.82 to -US$1.29 per share. Revenue forecast of US$7.27m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$16.00 unchanged from last update. Share price rose 2.9% to US$11.39 over the past week. Major Estimate Revision • Mar 19
Consensus revenue estimates increase to US$6.80m The consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$1.40m to US$6.80m. Forecast losses expected to reduce from -US$1.12 to -US$1.03 per share. Pharmaceuticals industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$12.00 unchanged from last update. Share price rose 27% to US$10.07 over the past week. Analyst Estimate Surprise Post Earnings • Mar 14
Earnings beat expectations Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 100% compared to a 22% growth forecast for the Pharmaceuticals industry in the US. Recent Insider Transactions • Mar 10
Executive Chairman recently bought US$200k worth of stock On the 5th of March, Michael Valentino bought around 25k shares on-market at roughly US$8.00 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months. Is New 90 Day High Low • Feb 10
New 90-day high: US$6.89 The company is up 99% from its price of US$3.47 on 11 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: US$6.50 The company is up 103% from its price of US$3.21 on 22 September 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 14
Earnings miss expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.9%. Over the next year, revenue is forecast to grow 1,828%, compared to a 21% growth forecast for the Pharmaceuticals industry in the US. Is New 90 Day High Low • Nov 14
New 90-day high: US$4.31 The company is up 29% from its price of US$3.35 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.